Breaking News Instant updates and real-time market news.

GLMD

Galmed

$14.44

1.69 (13.25%)

, OSK

Oshkosh

$72.36

0.83 (1.16%)

10:11
07/13/18
07/13
10:11
07/13/18
10:11

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Galmed (GLMD) initiated with a Buy at Stifel. 2. Oshkosh (OSK) initiated with a Buy at Longbow. 3. Domo (DOMO) was initiated with a Positive at Susquehanna and an Outperform at Oppenheimer. 4. ADMA Biologics (ADMA) initiated with an Outperform at Oppenheimer. 5. Urban Outfitters (URBN) initiated with a Neutral at Wedbush and an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

GLMD

Galmed

$14.44

1.69 (13.25%)

OSK

Oshkosh

$72.36

0.83 (1.16%)

DOMO

Domo

$20.68

0.83 (4.18%)

ADMA

ADMA Biologics

$4.95

0.42 (9.27%)

URBN

Urban Outfitters

$45.20

0.9 (2.03%)

PLCE

Children's Place

$116.20

1.95 (1.71%)

  • 04

    Dec

  • 05

    Dec

GLMD Galmed
$14.44

1.69 (13.25%)

07/12/18
07/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Galmed (GLMD) initiated with an Overweight at Cantor Fitzgerald. 2. VF Corp. (VFC) initiated with a Buy at Deutsche Bank. 3. NetApp (NTAP) initiated with a Buy at Guggenheim. 4. Rayonier Advanced Materials (RYAM) initiated with a Buy at Berenberg. 5. Ebix (EBIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
STFL
07/13/18
INITIATION
Target $35
STFL
Buy
Galmed initiated with a Buy at Stifel
Stifel analyst Adam Walsh initiated Galmed with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH.
07/11/18
CANT
07/11/18
INITIATION
Target $59
CANT
Overweight
Galmed initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Elemer Piros initiated Galmed with an Overweight and $59 price target.
07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
OSK Oshkosh
$72.36

0.83 (1.16%)

07/13/18
LBOW
07/13/18
INITIATION
Target $88
LBOW
Buy
Oshkosh initiated with a Buy at Longbow
Longbow analyst Faheem Sabeiha initiated Oshkosh with a Buy and $88 price target.
03/19/18
DBAB
03/19/18
UPGRADE
Target $99
DBAB
Buy
Oshkosh upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase upgraded Oshkosh to Buy and raised her price target for the shares to $99 from $90. The analyst reevaluated ratings in the Machinery space following the recent pullback in the shares.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/18
RHCO
04/20/18
NO CHANGE
Target $110
RHCO
Buy
Oshkosh price target raised to $110 from $106 at SunTrust
SunTrust analyst Charles Brady raised his price target on Oshkosh to $110 ahead of next week's earnings, citing "continued strength" in Access Equipment and RCV sales in the commercial segment. Brady says he also expects the company to raise its FY18 guidance and for management commentary to be favorable as the company enters the height of construction season with more orders placed in Q2 and the coming quarters. The analyst keeps his Buy rating on Oshkosh but also points to anticipated earnings call discussion around "material cost inflation and increased freight cost".
DOMO Domo
$20.68

0.83 (4.18%)

07/13/18
SUSQ
07/13/18
INITIATION
Target $24
SUSQ
Positive
Domo initiated with a Positive at Susquehanna
Susquehanna analyst Anne Meisner initiated Domo with a Buy and $24 price target.
07/13/18
SUSQ
07/13/18
INITIATION
Target $24
SUSQ
Positive
Domo initiated with a Positive on solid product offering at Susquehanna
Susquehanna analyst Anne Meisner initiated Domo with a Positive and $24 price target based on a solid product offering and confidence in the seasoned management team. Mesiner said shares trade at a deep discount to other high-growth software companies, which is deserved given competitive dynamics and cash burn, but said the company is investing to capture a significant market opportunity, and devoted substantial amounts of capital to R&D and sales & marketing.
ADMA ADMA Biologics
$4.95

0.42 (9.27%)

06/13/18
LTCO
06/13/18
NO CHANGE
Target $7.5
LTCO
Buy
ADMA Biologics price target lowered to $7.50 from $10 at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for ADMA Biologics to $7.50 to reflect the recent financing and increasing risk of delay to timelines for completion of FDA inspection of the company's Boca Raton plasma fractionation facility. The analyst, however, reiterates a Buy rating on the shares. He continues to believe once the facility remediation is complete there is "significant commercial potential" for RI-002.
06/07/18
06/07/18
NO CHANGE

ADMA Biologics files to sell common stock, no amount given
Raymond James & Associates, Inc. is acting as the sole book-running manager of the proposed offering.
07/13/18
OPCO
07/13/18
INITIATION
Target $13
OPCO
Outperform
ADMA Biologics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated ADMA Biologics with an Outperform rating and $13 price target, telling investors in a research note that he sees ADMA as an early turnaround story that is set to outperform heading into catalysts in the second half of the year and beyond. Although shares are up ~40% YTD, Gershell believes the market has trailed the company's strengthening fundamentals due to a lack of regulatory visibility, providing an attractive opportunity for investors.
11/14/17
11/14/17
UPGRADE
Target $5

Outperform
ADMA Biologics upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded ADMA Biologics to Outperform from Market Perform with a $5 price target. Analyst Reni Benjamin has increased confidence that RI-002 will be approved once manufacturing issues are resolved, said the Biotest acquisition should provide downside protection, and believes last week's equity raise removes an overhang.
URBN Urban Outfitters
$45.20

0.9 (2.03%)

07/09/18
KEYB
07/09/18
DOWNGRADE
KEYB
Sector Weight
Urban Outfitters downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Edward Yruma downgraded Urban Outfitters to Sector Weight. The analyst downgraded shares of Nordstrom (JWN).
07/13/18
WEDB
07/13/18
INITIATION
Target $50
WEDB
Neutral
Urban Outfitters a 'compelling' turnaround story, says Wedbush
Wedbush analyst Jen Redding initiated shares of Urban Outfitters with a Neutral rating and $50 price target, telling investors in a research note that she views Urban as a "compelling" turnaround story with meaningful multi-year runway ahead driven by gross margin expansion and revenue growth. Still, Redding says she is on the sidelines with a Neutral, as shares trade a distance of about 9% from the 52-week high which sits at $48.24, and holds concerns over if short-term expectations into print have run up too much at this point in the quarter.
07/13/18
WEDB
07/13/18
INITIATION
Target $50
WEDB
Neutral
Urban Outfitters initiated with a Neutral at Wedbush
07/10/18
07/10/18
DOWNGRADE

Sector Weight
Urban Outfitters downgraded to Sector Weight on risk/reward prospects at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Urban Outfitters to Sector Weight from Overweight to reflect more balanced near-term risk reward prospects. The analyst believes comp comparisons will get increasingly difficult in the 2H and earnings growth will need to be driven by gross margin expansion.
PLCE Children's Place
$116.20

1.95 (1.71%)

07/13/18
WEDB
07/13/18
INITIATION
Target $150
WEDB
Outperform
Children's Place initiated with an Outperform at Wedbush
07/13/18
WEDB
07/13/18
INITIATION
Target $150
WEDB
Outperform
Children's Place initiated with an Outperform at Wedbush
Wedbush analyst Jen Redding initiated shares of Children's Place with an Outperform rating and $150 price target, telling investors in a research note that inventory is well positioned and its markdown rate has stabilized, according to her e-commerce model. Redding believes there is runway into Q2 for shares now that weather has turned more seasonable from the extended winter weather of Q1, and views Children's Place as the best-in-class specialty retailer longer-term.
06/15/18
OPCO
06/15/18
NO CHANGE
Target $150
OPCO
Outperform
Children's Place risk-return 'compelling' into Q2 results, says Oppenheimer
Oppenheimer analyst maintained an Outperform rating and $150 price target for Children's Place, telling investors that she believes the risk-return "is compelling" into Q2 results. She believes quarter-to-date comps are still above the high single digit guide and sets up well.
05/14/18
05/14/18
UPGRADE
Target $150

Outperform
Children's Place upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Anna Andreeva upgraded Children's Place to Outperform from Perform and raised her price target on the shares to $150 from $135, citing multiple initiatives still ahead while expectations re-set.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$52.12

0.7 (1.36%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Upgrade
Wells Fargo rating change  »

Wells Fargo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

CVS

CVS Health

$74.49

1.33 (1.82%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Conference/Events
Economic Club of Washington, D.C. to hold luncheon meeting »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

WTI

W&T Offshore

$7.38

0.12 (1.65%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Upgrade
W&T Offshore rating change  »

W&T Offshore upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYME

Tyme Technologies

$2.52

-0.11 (-4.18%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Hot Stocks
Tyme Technologies appoints Michele Korfin as CCO »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$35.00

0.87 (2.55%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Conference/Events
Teradata to hold customer conference »

Teradata Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

AMTD

TD Ameritrade

$50.52

0.72 (1.45%)

08:23
10/15/18
10/15
08:23
10/15/18
08:23
Conference/Events
TD Ameritrade to hold a daily program »

TD Ameritrade Network, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IMPV

Imperva

$55.32

0.05 (0.09%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$74.60

0.365 (0.49%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Hot Stocks
Discover reports September charge-off rate 3.2% vs. 3.1% last month »

Reports September 30 or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$188.69

1.55 (0.83%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
10/15/18
10/15
08:20
10/15/18
08:20
General news
NY Empire State index preview: »

NY Empire State index…

XLK

Technology Select Sector SPDR

$70.83

2.15 (3.13%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$36.23

0.53 (1.48%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Conference/Events
Ceridian to hold a conference »

INSIGHTS 2018 will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

XLE

Energy Select Sector SPDR

$72.95

0.2 (0.27%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$108.56

2.05 (1.92%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.78

0.18 (0.34%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$93.18

1.37 (1.49%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$98.33

0.45 (0.46%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Recommendations
Hasbro analyst commentary  »

Hasbro new digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

XLU

Utilities SPDR

$52.97

-0.04 (-0.08%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.38

0.29 (0.56%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$91.07

1.37 (1.53%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GAIN

Gladstone Investment

$10.57

-0.13 (-1.22%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Hot Stocks
Gladstone Investment makes additional investment in portfolio company »

Gladstone Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.